The two studies describe methods for identifying off-target mutations associated with cell-type-specific SNPs and detecting potential off-target cleavage sites.
The University of California, University of Vienna, and researcher Emmanuelle Charpentier, as well as their commercial partners, are linked by the agreement.
After CRISPR/Cas9 makes a double-strand break in DNA and the cell repairs it, the same set of mutations crop up again and again based on the genomic sequence.
While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.
Caribou will license its CRISPR technology to Genus to help it create pigs that are resistant to Porcine Reproductive and Respiratory Syndrome Virus.
The financing round includes new investors Anterra Capital, Heritage Group, Maverick Capital Ventures, and Pontifax AgTech.
The Berkeley, California-based company is aiming to turn CRISPR into a platform technology for clinical and industrial applications.
The USPTO has become involved in the CRISPR-Cas9 patent dispute.
As the interference proceeding to resolve claims in foundational CRISPR patents draws near, Caribou has given IDT worldwide rights to sell RUO reagents.
In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.
An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.
In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.
In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.